Characteristics of a <i>CCL21</i> Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung Cancer
Michael S. Oh(Northwestern University), Bin Liu(University of California, Los Angeles), Raymond J. Lim(University of California, Los Angeles), Zhe Jing(University of California, Los Angeles), Ramin Salehi‐Rad(University of California, Los Angeles), Linh M. Tran(University of California, Los Angeles), Edward B. Garon(University of California, Los Angeles), Kostyantyn Krysan(University of California, Los Angeles), Aaron Lisberg(University of California, Los Angeles), Camelia Dumitras(University of California, Los Angeles), Steven M. Dubinett(University of California, Los Angeles), Shahed Tappuni(University of California, Los Angeles)
Cited by 10
Related Papers
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
|Nature Medicine|2010|338
Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo
|The Journal of Immunology|2000|202